Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT02776475
Other study ID # 16-019
Secondary ID
Status Terminated
Phase N/A
First received
Last updated
Start date August 4, 2016
Est. completion date May 27, 2021

Study information

Verified date October 2020
Source TriHealth Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This prospective one group cohort study seeks to investigate the effects of sacral neuromodulation on urinary urgency, frequency and urge incontinence are maintained after the simulator device is temporarily turned off for a period of four weeks.


Description:

Urinary urgency, frequency, and urge incontinence are very common symptoms, affecting up to one in three adults in the United States. The total economic cost of these disorders was estimated to be above $12 billion in the year 2000, with the vast majority being for women. Sacral neuromodulation (SNM) has become a popular and successful treatment option for people who suffer from these conditions. Sacral neuromodulation device delivers electrical pulses to an area near the sacral nerve. There has been some data published which showed that for patients with fecal incontinence, symptom relief can persist for significant time periods despite having the stimulator device turned off. Based on their findings, potential exists to prolong battery life if patients can cycle the on and off periods for their device while keeping their symptoms stable. The typical battery life of the implantable pulse generator (IPG) is approximately 5 years depending on the system settings. When the IPG is at the end of its battery life, a new IPG must be implanted. The cost of replacing the IPG ranges from $13,952 to $16,470. IPG replacement must be done in the operating room and requires the patient to undergo anesthesia and its associated risks. This study will investigate whether the symptoms of urinary urgency, frequency, and urge incontinence remain stable in patients with SNM with the device turned off for a period of four weeks. Current Cincinnati Urogynecology Associates (CUA) patients who are currently being successfully treated with sacral neuromodulation for the primary diagnosis of urinary urge incontinence or urgency and frequency who elect participate in the study will have the device turned off for four consecutive weeks. Their symptoms will be monitored during this time period.


Recruitment information / eligibility

Status Terminated
Enrollment 18
Est. completion date May 27, 2021
Est. primary completion date May 27, 2021
Accepts healthy volunteers No
Gender Female
Age group 18 Years to 85 Years
Eligibility Inclusion Criteria: - Women, aged 18-85 with who have previously had the InterStim device implanted and have experienced good control of their symptoms for at least one year. Exclusion Criteria: - Patients with less than 6 months of expected battery life on their device established at office testing. - Patients with poor control of their symptoms within the last one year. - Patients with degenerative neurological disorders or spinal cord injuries. - Patients with cognitive disabilities or those lacking the mental capacity to understand and answer questionnaires. - Patients who are pregnant or may become pregnant.

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Sacral neuromodulation device turned off
Each patient will be to have the sacral neuromodulation device turned off for four consecutive weeks.

Locations

Country Name City State
United States Cincinnati Urogynecology Associates Cincinnati Ohio

Sponsors (1)

Lead Sponsor Collaborator
TriHealth Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary The difference in scores on the International Consultation on Incontinence Questionnaire - Short Form (ICIQ-SF) from baseline with the SNM device compared to having the device turned off for a period of four weeks The outcome measure is assessing change between initial baseline and 4 weeks after turning off the device.
Primary The difference in scores on the International Consultation on ICIQ-SF from baseline with the SNM device compared to having the device turned off for a period of up to six months The outcome measure is assessing change between initial baseline and 6 months after turning off the device.
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03556891 - Pivotal Study of eCoin for Overactive Bladder With Urgency Urinary Incontinence N/A
Completed NCT01957137 - InterStim® Sacral Nerve Modulation Cycling Study N/A
Recruiting NCT04305743 - Post-procedural Pain Associated With 5 Versus 20 Intravesical Injections of Onabotulinumtoxin A Phase 4
Completed NCT05064384 - Axonics SacRal NeuromodulaTIon System RegisTRY Study
Completed NCT04016324 - InterStim Basic Evaluation Lead Post-Market Clinical Follow-up Study N/A
Completed NCT02600715 - Reduction of Bladder Injection Pain With Belladonna Opiate Suppository Phase 4
Completed NCT01009333 - InterStim Therapy Programming Study N/A
Active, not recruiting NCT05308979 - Intradetrusor Botulinum Toxin A for OAB Via 1 Versus 10 Injections: A Randomized Clinical Trial Phase 4
Completed NCT03655054 - eCoin for OAB Feasibility Follow-on Study N/A
Recruiting NCT05309993 - INvestigation of TENS Efficacy Versus Posterior Tibial Nerve Stimulation for Overactive Bladder N/A
Completed NCT01226706 - Efficacy of Botulinum Toxin Type A for the Treatment of Non-neurogenic Urinary Urge Incontinence N/A
Enrolling by invitation NCT06085846 - Real-World Registry - The Vivally® System
Completed NCT06222515 - Bladder Diary for Female Storage LUTS
Recruiting NCT05685433 - A Real World Study of eCoin for Urgency Urinary Incontinence: Post Approval Evaluation (RECIPE) N/A
Recruiting NCT03742206 - Comparison of Two Forms of Transcutaneous Electrical Stimulation in Overactive Bladder N/A
Completed NCT04063852 - PTNS on Urinary and Global Quality of Life in MS Patients
Completed NCT03335761 - InterStim® Amplitude Study N/A
Recruiting NCT06217328 - RESTORE: An RCT to Evaluate the Efficacy of the Revi System N/A
Recruiting NCT06161506 - Surface Electrical Stimulation for Urinary Incontinence in Men Treated for Prostate Cancer Phase 2
Active, not recruiting NCT05543382 - Cycling Study With the Axonics System